How does adding PD-(L)1 inhibitors to platinum-etoposide treatment of small cell lung cancer improve survival outcomes?

Formelli MG, Di Odoardo A, Andrini E, Lamberti G

Open source

DOI
10.1080/14737140.2026.2738624
Published
2026 Sep 22
Container
Expert review of anticancer therapy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14737140.2026.2738624,
  title = {How does adding PD-(L)1 inhibitors to platinum-etoposide treatment of small cell lung cancer improve survival outcomes?},
  author = {Formelli MG and Di Odoardo A and Andrini E and Lamberti G},
  year = {2026},
  journal = {Expert review of anticancer therapy},
  doi = {10.1080/14737140.2026.2738624},
  url = {https://doi.org/10.1080/14737140.2026.2738624}
}

RIS

TY  - JOUR
TI  - How does adding PD-(L)1 inhibitors to platinum-etoposide treatment of small cell lung cancer improve survival outcomes?
AU  - Formelli MG
AU  - Di Odoardo A
AU  - Andrini E
AU  - Lamberti G
PY  - 2026
JO  - Expert review of anticancer therapy
DO  - 10.1080/14737140.2026.2738624
UR  - https://doi.org/10.1080/14737140.2026.2738624
ER  - 

APA

MG, F., A, D. O., E, A., & G, L. (2026). How does adding PD-(L)1 inhibitors to platinum-etoposide treatment of small cell lung cancer improve survival outcomes?. Expert review of anticancer therapy. https://doi.org/10.1080/14737140.2026.2738624

Source records